Company overview
CryoLogyx is a University of Warwick spin-out biotechnology company developing innovative cryopreservation technology for frozen, ready-to-use cells. The company supplies assay-ready pre-plated cells and macromolecular cryoprotectants (CryoShield) for pharmaceutical R&D, drug screening, diagnostics, and cell-based therapies. Their polymer-based technology achieves mid-to-high 90% cell recovery rates compared to 10% with conventional methods, reducing preparation time from days to under one minute.
Cryologyx is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include cryopreservation, assay-ready cells, drug discovery, cell therapy, cryoprotectants.
Products and technologies associated with Cryologyx include Assay — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://www.cryologyx.com
- Markets served
- United States & Americas
- Keywords
- cryopreservation, assay-ready cells, drug discovery, cell therapy, cryoprotectants
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What is CryoLogyx's core technology?
- CryoLogyx develops synthetic macromolecular cryoprotectants—polymers that protect cells against cold stress during freezing and storage. Their proprietary CryoShield technology enables cells to be cryopreserved while attached to plastic culture plates, eliminating a major bottleneck in drug discovery workflows.
- What are the key performance benefits compared to conventional cryopreservation?
- CryoLogyx achieves mid-to-high 90% cell recovery rates versus approximately 10% with traditional methods. Cells thaw and become assay-ready in less than 24 hours rather than the two weeks currently required, reducing preparation work by approximately 10-fold.
- Which cell types and applications does CryoLogyx support?
- CryoLogyx supplies assay-ready pre-plated cells for biotech R&D, drug screening, diagnostics, and cell-based therapies. Their technology has been validated on three of the most widely used cell lines globally and works across a range of cell types for medicines discovery and viral screening applications.
- What regulatory and funding support does CryoLogyx have?
- CryoLogyx received £300,000 in funding from InnovateUK to develop innovative cryopreservation agents. The company's polymer cryoprotectant technology has been published in peer-reviewed research and validated through studies at the University of Warwick's Department of Chemistry and Warwick Medical School.
- Where is CryoLogyx located and when was it founded?
- CryoLogyx is based in Coventry, United Kingdom, as a spin-out from the University of Warwick. The company was founded in 2021 and operates as an early-stage biotechnology manufacturer.
Related editorial coverage
- Drug Discovery USA 2026: What to Expect
- Allogene CEO David Chang Steps Down: Implications for the Biotech Sector
- Cencora-Kite Agreement: A New Era for CAR T-cell Therapy Commercialization
- Legend Biotech's In Vivo CAR-T Data Sparks Stock Surge: A Catalyst Tracking Analysis
- Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO
- Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy
Explore lab tools and QA/QC resources for R&D teams.
